| 1.3625 0.073 (5.62%) | 04-26 14:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.42 | 1-year : | 3 |
| Resists | First : | 2.07 | Second : | 2.56 |
| Pivot price | 1.65 |
|||
| Supports | First : | 1.26 | Second : | 1.05 |
| MAs | MA(5) : | 1.44 |
MA(20) : | 1.82 |
| MA(100) : | 1.46  |
MA(250) : | 1.49 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5 |
D(3) : | 5.2 |
| RSI | RSI(14): 36.2 |
|||
| 52-week | High : | 2.56 | Low : | 0.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NXTC ] has closed above bottom band by 16.7%. Bollinger Bands are 70.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 48 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.25 - 1.26 | 1.26 - 1.27 |
| Close: | 1.28 - 1.29 | 1.29 - 1.3 |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Mon, 08 Apr 2024
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 - GlobeNewswire
Wed, 27 Mar 2024
Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely? - Yahoo Finance
Wed, 27 Mar 2024
NextCure Inc (NXTC) is up 31.91% in a Week, Should You Hold? - InvestorsObserver
Sat, 23 Mar 2024
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate - Simply Wall St
Thu, 21 Mar 2024
Healthcare Stocks on the Move Thursday: XFOR, CMAX, CDIO, NXTC, APYX, WORX, VINC, EXAI - InvestorsObserver
Thu, 21 Mar 2024
NextCure Inc to Engage with Investors in Informal Talks - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 50.2 (%) |
| Shares Short | 994 (K) |
| Shares Short P.Month | 123 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.1 % |
| Return on Equity (ttm) | -44.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -0.61 |
| PEG Ratio | 0 |
| Price to Book value | 0.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|